Propecia lowers dihydrotestosterone (DHT) around susceptible hair follicles, helping slow male pattern hair loss and support hair retention. It is intended for adult men with androgenetic alopecia…
Propecia lowers dihydrotestosterone (DHT) around susceptible hair follicles, helping slow male pattern hair loss and support hair retention. It is intended for adult men with androgenetic alopecia, with visible changes developing gradually during continuous daily treatment.
Propecia contains finasteride in an oral tablet formulation for adult men with male pattern baldness, also called androgenetic alopecia. Finasteride belongs to the 5-alpha-reductase type II inhibitor class.
Finasteride belongs to the 5-alpha-reductase type II inhibitor class. Propecia reduces the conversion of testosterone into DHT, the androgen linked to progressive miniaturisation of susceptible scalp follicles.
It is intended for adult men with androgenetic alopecia, with visible changes developing gradually during continuous daily treatment.
Propecia contains finasteride 1 mg in an oral tablet formulation for adult men with male pattern baldness, also called androgenetic alopecia.
Propecia contains finasteride in an oral tablet formulation for adult men with male pattern baldness, also called androgenetic alopecia. The condition commonly affects the frontal hairline, temples, and crown because genetically sensitive follicles gradually shrink under the influence of DHT.
Dosing differs between strengths and between users, so there is no single amount that suits everyone. Different strengths follow different treatment regimens and should not be substituted for one another.
Finasteride belongs to the 5-alpha-reductase type II inhibitor class. Propecia reduces the conversion of testosterone into DHT, the androgen linked to progressive miniaturisation of susceptible scalp follicles.
The treatment objective is usually preservation first. Regrowth may occur, but maintaining existing hair is an important clinical outcome because untreated follicle miniaturisation can become harder to reverse.
Testosterone is converted into DHT by the enzyme 5-alpha-reductase. In genetically sensitive follicles, DHT shortens the active growth phase and gradually produces finer, shorter hairs. Finasteride inhibits the type II form of this enzyme, reducing DHT exposure in the scalp and serum.
The effect is selective rather than a complete shutdown of male hormones. Finasteride does not remove testosterone from the body, and it does not eliminate every androgen pathway involved in hair biology. Its main role is to reduce the DHT signal affecting vulnerable follicles.
The European Medicines Agency evaluates finasteride products through product information covering indications, adverse effects, and monitoring considerations [1].
The appropriate Propecia dose depends on the strength and the individual user, so there is no single amount that suits everyone. It can be taken with food or on an empty stomach. The tablet should be swallowed with water rather than chewed.
The treatment plan may be adjusted when a prescriber identifies a medical reason to do so. A higher dose does not automatically produce better scalp results and can increase exposure to adverse effects.
Breaking or crushing tablets creates a handling concern for women who are pregnant or may become pregnant. The active ingredient can be absorbed through the skin, so a broken tablet should not be handled by this group.
Propecia and topical minoxidil act through different biological pathways. Finasteride reduces DHT formation, while minoxidil is applied to the scalp and supports follicle activity through a local mechanism that is not based on DHT inhibition.
| Approach | Main mechanism and use |
|---|---|
| Propecia | Oral finasteride 1 mg reduces DHT formation and is used for male androgenetic alopecia. |
| Topical minoxidil | Applied to the scalp; supports hair growth through a local follicle-directed mechanism. |
| Combined approach | Uses different mechanisms and may be considered when a clinician judges that additional treatment is appropriate. |
Propecia is convenient for men who prefer once-daily oral treatment, but it can produce systemic adverse effects, including sexual or mood-related symptoms. Topical minoxidil avoids finasteride-related hormonal enzyme inhibition, yet it may cause scalp irritation, unwanted facial hair, or an early increase in shedding.
Combination treatment is not automatically better for every person. The diagnosis, pattern of loss, tolerance, other medicines, and willingness to maintain a long-term routine all affect the choice. A 2022 systematic review indexed in PubMed found that treatment decisions for androgenetic alopecia should account for both efficacy and tolerability rather than relying on one universal regimen [4].
Several practical errors can make Propecia seem less useful than it is:
One frequent mistake is stopping as soon as shedding improves. Reduced shedding may mean the treatment is helping maintain follicles, not that the underlying tendency has disappeared.
Another is treating the tablet as a short course. Propecia controls an ongoing biological process while it is taken; it does not permanently remove genetic sensitivity to DHT.
Finasteride is contraindicated in women who are pregnant or may become pregnant because inhibition of DHT formation can affect development of male external genitalia in a male fetus. Women in this group must not handle crushed or broken tablets.
Propecia is not indicated for children or adolescents. It is intended for adult men with male pattern hair loss.
Finasteride is not for women who are pregnant or may become pregnant, and damaged tablets should be kept away from them. Propecia is intended for adult men, not children or adolescents.
Medical review is needed before treatment when there is:
A clinician interpreting a PSA result must know that the patient takes finasteride, because the measured value may need adjustment.
This consideration is included in regulatory product information and prostate assessment guidance [3].
Finasteride 1 mg was generally tolerated in clinical trials, but it can cause adverse effects. The most discussed reactions involve sexual function. In controlled studies, decreased libido, erectile dysfunction, and ejaculation disorders were reported in a small percentage of men, with rates generally around 1–2% and close to placebo levels in many trials [2].
Possible reactions include:
Sexual symptoms improved in many men after stopping treatment or while continuing treatment, but persistent symptoms have also been reported after discontinuation. The frequency, cause, and duration of persistent symptoms remain subjects of medical research, so they should not be dismissed or assumed to be permanent.
A lower libido may have several causes, including stress, depression, relationship difficulties, sleep problems, alcohol use, metabolic disease, and other medicines. The timing of symptoms matters. A symptom that begins after treatment starts deserves a clinical review rather than automatic attribution to finasteride.
Reduced semen volume does not necessarily mean infertility. Finasteride can alter semen parameters in some men, and reported changes have often improved after discontinuation. Men being assessed for fertility should disclose finasteride use to the clinician managing that assessment.
Mood changes require prompt attention. New depression, marked anxiety, or thoughts of self-harm need urgent medical support.
In clinical practice, physicians usually set two expectations early: the first goal is slowing further loss, and the second is allowing enough time to judge whether regrowth occurs. A visible change after only a few weeks is unlikely because the hair cycle changes slowly.
A dermatologist will often examine the distribution of thinning before recommending finasteride. A receding hairline with crown thinning may fit androgenetic alopecia, while abrupt patchy loss, scalp scaling, or inflammation may point to another diagnosis.
Doctors also ask about sexual function, mood, fertility plans, liver disease, and prostate screening. These questions are not routine formalities. They help identify adverse effects, interpret PSA results correctly, and select a treatment plan that can be maintained.
A useful clinical rule is to assess progress at six months and make a fuller decision around twelve months, provided treatment has been taken consistently. Stopping and restarting repeatedly makes it difficult to judge the true response.
Stopping Propecia removes finasteride’s DHT-lowering effect, so hair maintained during treatment may gradually be lost over the following 6 to 12 months. A taper is generally not required because finasteride does not cause the withdrawal syndrome associated with some medicines that act directly on the brain. The European Medicines Agency product information reviewed in 2024 describes treatment as continuous rather than requiring a dose-reduction schedule. Any decision to stop should also account for sexual, mood, fertility, or other adverse effects. A prescriber can discuss alternative hair-loss strategies if treatment is stopped.
Propecia is not indicated for children or adolescents because its approved hair-loss use applies to adult men. A young person with thinning hair needs assessment for causes such as alopecia areata, scalp disease, nutritional problems, or endocrine conditions instead of self-starting finasteride. The WHO medicine-safety principles published in 2023 support age-appropriate prescribing and diagnosis before long-term drug treatment. The tablet should not be used to treat routine adolescent shedding without a specific clinical assessment.
Some men notice reduced shedding by about three months, while visible stabilisation or early regrowth commonly requires six months. A more reliable assessment of density is usually made after approximately twelve months of daily use. Clinical trial information reviewed by the FDA in 2022 describes gradual benefit rather than an immediate cosmetic response. Hair photographs taken at consistent intervals are more informative than checking the mirror each day.
Pregnancy rules out exposure to finasteride, and women who are pregnant or may become pregnant must not use Propecia or handle crushed tablets. The reason is a potential risk to the development of male fetal external genitalia caused by reduced DHT formation. The EMA (2024) pregnancy warning in its finasteride product information remains a specific contraindication. Adult men with a history of depression, liver disease, or fertility concerns may require individual assessment rather than automatic exclusion.
The tablet should be swallowed whole with water and should not be chewed or crushed. Damaged tablets create a handling risk for women who are pregnant or may become pregnant because finasteride can be absorbed through the skin. FDA labeling reviewed in 2023 advises avoiding contact with broken or crushed tablets in this group. Splitting the tablet also makes accurate daily dosing less reliable.
Propecia may be taken with food or without food, so meals do not determine whether the tablet can be used. Choosing one consistent time can make daily adherence easier, especially when treatment continues for many months. MOHAP medicine-use principles in 2025 support taking oral medicines according to their approved administration instructions rather than changing timing to chase a faster effect. Food does not replace the need for the prescribed daily schedule.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
